Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly
due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1,
alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating
the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies
with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer
patients has opened the way to novel possibilities of integrating therapies. The identification of
biomarkers of tumor response to these combinations represents a challenge in RCC, together with the
research for the best partner for immunotherapy in metastatic patients. In this review we illustrated
preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART
cells in RCC.
Keywords: CAR-T cells, immunocheckpoint inhibitors, immunotherapy, programmed-death-1, radiation therapy, renal cell
Escudier B, Barthelemy P, Ravaud A, Negrier S, Needle MN, Albiges L. ivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018; (6_suppl): 618-8.
Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). J Clin Oncol 2018; (6_suppl): 578-8.
Rights & PermissionsPrintExport